MGNX - MacroGenics Inc logo

MacroGenics Inc

MGNX

MacroGenics, Inc. develops and commercializes antibody-based therapeutics for cancer treatment. Its pipeline includes bispecific molecules and antibody-drug conjugates targeting various solid tumors and hematological malignancies in clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$142today

Score Overview

1 Year
Score
Net Growth80.44%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth12.16%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.5
Net Growth92.35%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth121.66%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth75.07%
Net Trend60%
Net Income Consistency
Rev Growth93.66%
Rev Trend70%
Revenue Consistency
All Time
Scoreโ€”
Net Growthโ€”
Net Trend58%
Net Income Consistency
Rev Growth195.44%
Rev Trend62%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where MacroGenics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. MGNX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 3.63โ€”
1 Year2025-10-22
$ 1.9586.15%
5 Years2021-10-22
$ 19.11-81.00%
10 Years2016-10-21
$ 25.57-85.80%
All Time2013-10-10
$ 24.99-85.47%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 167M-$ 14M$ 173M
2025$ 149M-$ 74M$ 189M
2024$ 148M-$ 66M$ 201M
2023$ 57M-$ 9M$ 229M
2022$ 151M-$ 120M$ 154M
2021$ 75M-$ 190M$ 243M
2020$ 97M-$ 117M$ 272M
2019$ 62M-$ 151M$ 215M
2018$ 60M-$ 171M$ 232M
2017$ 155M-$ 19M$ 305M
2016$ 86M-$ 58M$ 276M
2015$ 100M-$ 20M$ 339M
2014$ 47M-$ 38M$ 157M
IPO2013$ 56M$ 116M
MGNX - MacroGenics Inc logo

MacroGenics Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 97M to $ 149M and net income went from -$ 117M to -$ 74M. Revenue increased in 4 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 100M to $ 149M and net income went from -$ 20M to -$ 74M. Revenue increased in 7 of those 10 years; net income in 6.

MacroGenics Inc currently holds a 5-year HDB Score of 6.5 out of 10. How the HDB Score is calculated.

Membership

Explore MGNX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies